BioSpace News Archive

Eli Lilly and Company (NYSE: LLY) announced today that REYVOW™ (lasmiditan) C-V 50 mg and 100 mg tablets, an oral medication for the acute treatment of migraine with or without aura in adults, is now available for prescription

MFG Chemical, a global leader in specialty and custom chemical manufacturing, is improving its manufacturing capabilities in Dioctyl Sodium Sulfosuccinate (DOSS) through the current upgrading of its three Dalton, Georgia plants.

Three new members have joined the CARESTAR Foundation’s Board of Directors this month, building the nonprofit’s strength with diverse experience in grantmaking, emergency medicine, and health policy, all aimed at improving health care delivery for the people of California . “The remarkab

Centene Corporation (NYSE: CNC) announced today the launch of a new community partnership in Louisiana. Social Health Bridge, established in 2019 to help community based organizations and healthcare entities work more effectively to address social determinants of health, partnered with the NHP Foundation (NHPF) and its affiliate

Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today the successful initial verification of its screening test designed to identify the presence of the novel coronavirus that originated in China before spreading across the world, and that the test will soon be ready for validation in and subsequent distribution to any appropriate venue across the globe.

Maxar Technologies, a trusted partner and innovator in Earth Intelligence and Space Infrastructure, announced that it was selected by NASA to perform an in-space assembly demonstration using a lightweight robotic arm.

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that the U.S. Food and Drug Administration (FDA) approved PALFORZIA™ [Peanut (Arachis hypogaea) Allergen Powder-dnfp].

Afya Limited announced the closing of its acquisition, through its wholly-owned subsidiary Afya Participações S.A., of 100% of the total share capital of UniRedentor - Sociedade Universitária Redentor, or Uniredentor.

Denali Therapeutics Inc. announced the closing of its upsized underwritten public offering of 9,000,000 shares of its common stock at a price to the public of $23.00 per share, which includes the exercise in full by the underwriters of their option to purchase additional shares.

The Company is pleased to announce that trading in the third quarter of the financial year has continued the favourable trends experienced in the first half